Screener
Glaukos GKOS US — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Glaukos in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Glaukos’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324201
| Line item | Three Months Ended / June 30, / United States / 2026 | Three Months Ended / June 30, / United States / 2025 | Three Months Ended / June 30, / International / 2026 | Three Months Ended / June 30, / International / 2025 | Three Months Ended / June 30, / Total / 2026 | Three Months Ended / June 30, / Total / 2025 |
|---|---|---|---|---|---|---|
| Glaucoma | $118,549 | $72,282 | $36,631 | $31,251 | $155,180 | $103,533 |
| Corneal Health | 28,190 | 18,237 | 2,240 | 2,350 | 30,430 | 20,587 |
| Total | $146,739 | $90,519 | $38,871 | $33,601 | $185,610 | $124,120 |
Item 1. Financial Statements
FAQ
- What is Glaukos's US — revenue?
- Glaukos (GKOS) reported US — revenue of $146.74M in Q2 2026.
- How has Glaukos's US — revenue changed year-over-year?
- Glaukos's US — revenue increased by 62.1% year-over-year, from $90.52M to $146.74M.
- What is the long-term trend for Glaukos's US — revenue?
- Over 4 years (2021 to 2025), Glaukos's US — revenue has grown at a 13.8% compound annual growth rate (CAGR), from $223.79M to $375.04M.
- What does US — revenue mean?
- This metric represents the total gross revenue generated from the sale of ophthalmic medical devices and related services within the United States market, excluding any sales-related taxes. It serves as the primary indicator of market penetration and commercial success for the company's glaucoma treatment portfolio in its largest geographic region.
Ask your AI about Glaukos's us — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude